(2-fluoro-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone | 1361475-06-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-fluoro-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone
• 英文别名: (2-Fluoro-3-hydroxyphenyl)-(6-hydroxy-1,3-benzothiazol-2-yl)methanone；(2-fluoro-3-hydroxyphenyl)-(6-hydroxy-1,3-benzothiazol-2-yl)methanone
• CAS: 1361475-06-0
• 化学式: C₁₄H₈FNO₃S
• 分子量: 289.287
• InChiKey: MTZNQBNVWKUPPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.7
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-甲氧基苯并噻唑 在 正丁基锂 、 吡啶盐酸盐 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 39.17h， 生成 (2-fluoro-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone
  参考文献：
  名称：

  Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1

  摘要：

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.

  DOI：

  10.1021/jm201711b

文献信息

• Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1
  作者：Alessandro Spadaro、Martin Frotscher、Rolf W. Hartmann

  DOI：10.1021/jm201711b

  日期：2012.3.8

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.